Trial Profile
A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2014
Price :
$35
*
At a glance
- Drugs Fluciclatide F-18 (Primary)
- Indications Solid tumours
- Focus Diagnostic use
- 25 Jul 2014 New trial record